Page last updated: 2024-09-03

5-(dimethylamino)-n-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide and daidzein

5-(dimethylamino)-n-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide has been researched along with daidzein in 1 studies

Compound Research Comparison

Studies
(5-(dimethylamino)-n-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide)
Trials
(5-(dimethylamino)-n-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide)
Recent Studies (post-2010)
(5-(dimethylamino)-n-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide)
Studies
(daidzein)
Trials
(daidzein)
Recent Studies (post-2010) (daidzein)
73081,885136753

Protein Interaction Comparison

ProteinTaxonomy5-(dimethylamino)-n-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide (IC50)daidzein (IC50)
rac GTPase-activating protein 1 isoform aHomo sapiens (human)91.26
Estrogen receptorHomo sapiens (human)2.97
Aldehyde dehydrogenase, mitochondrialHomo sapiens (human)9
UDP-glucuronosyltransferase 1A1 Homo sapiens (human)7.3
TransporterRattus norvegicus (Norway rat)0.45
Estrogen receptor betaHomo sapiens (human)1.6568

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Budhiraja, RD; Garg, A; Katyal, T1

Other Studies

1 other study(ies) available for 5-(dimethylamino)-n-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide and daidzein

ArticleYear
Combination of daidzein, hemin and bms182874 halts the progression of diabetes-induced experimental nephropathy.
    Endocrine, metabolic & immune disorders drug targets, 2013, Volume: 13, Issue:2

    Topics: Animals; Cytoprotection; Dansyl Compounds; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Progression; Drug Combinations; Drug Evaluation, Preclinical; Hemin; Isoflavones; Kidney; Male; Rats; Rats, Wistar; Streptozocin

2013